Neurocrine Biosciences Raises INGREZZA FY24 Net Product Sales Guidance To $2.25B-$2.3B
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has raised its FY24 net product sales guidance for INGREZZA to a range of $2.25 billion to $2.3 billion. The company also updated its expense guidance for R&D and SG&A expenses.
August 01, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences has increased its FY24 net product sales guidance for INGREZZA to $2.25 billion to $2.3 billion, indicating strong expected performance. The company also updated its R&D and SG&A expense guidance.
The raised sales guidance for INGREZZA suggests strong expected performance, which is likely to positively impact NBIX's stock price in the short term. The updated expense guidance provides clarity on the company's financial planning.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100